PB Fintech Q4 FY26 earnings call
In brief
PB Fintech reports FY26 insurance premium ₹29,934 Cr (+42% YoY), PAT ₹670 Cr (2.2% of premium); new protection grew 57%, health 68%.
- Management's tone
- Optimistic
- What was said
- Leaned positive
- Guidance
- Guidance held
- Analyst pushback
- Medium
- Stock, next session
- +1.27% (Nifty 50 +1.24%)
- FY26 insurance premium ₹29,934 Cr (+42% YoY); Q4 grew 46% YoY; new protection premium +57% for the year, +67% in Q4 with health +68%.
- Consolidated PAT ₹670 Cr = 2.2% of premium; renewal book ARR at ₹1,126 Cr in Q4, up 63% YoY from ₹689 Cr.
- Paisabazaar delivered operating-positive EBITDA in Q4; management expects a significantly positive year in FY27 on operating leverage.
- PB Health: first hospital ₹150 Cr revenue, ₹20-30 Cr profit; second hospital operational this month; raising external capital in late-stage conversations.
- New initiatives revenue grew 43% YoY with EBITDA margin at -4% and 5% contribution margin; PB Partners has 450,000 advisors covering 99% of PIN codes.
An AI read of the company's transcript · the filing
The numbers
The quarter, Q4 FY26
| This quarter | A year ago | Last quarter | Margin | |
|---|---|---|---|---|
| Revenue | ₹2,061 cr | +36.7% | +16.4% | |
| EBITDA (excl. other income) | ₹218 cr | +93.1% | +37.5% | 10.6% (7.5% a year ago) |
| Net profit | ₹261 cr | +53.0% | +37.9% | 12.7% (11.3% a year ago) |
| EPS (₹) | ₹5.65 | +51.5% | +37.5% |
From the company's filed results for the quarter ended 31 Mar 2026 (consolidated), not from the call. EBITDA here excludes other income, so it can differ from the figure management quotes.
What moved the numbers, as management explained it
- Post-September GST-affordability messaging lifted Q4 new-insurance-premium growth net of savings to 59% YoY from the 30-40% range seen over prior years. (one-off)
- Health ticket sizes pushed up by customer shift to >₹10 lakh sum-insured and unlimited-sum-insured launches; multi-year (4-5yr) term share in horizon.
- Savings business returned to growth after 3-4 quarters of softness, contributing to the 59% YoY new-premium growth.
- Renewal book ARR added ₹267 Cr over the last 12 months to ₹935 Cr LTM, with Q4 ARR at ₹1,126 Cr (+63% YoY), driving future profit per management.
- PB Connect wholesale POSP home-loan distribution stopped mid-January 2026, removing ~₹0.5 Cr/month of low-quality revenue with no profit impact. (one-off)
The numbers management led with
- New Protection Premium: ₹29,934 Cr at 57% YoY growth (67% in Q4)
- Renewal Revenue ARR (Q4): ₹1,126 Cr, up 63% YoY
- POSP Premium Concentration: 83% of premium from small agents (vs ~50% a year ago)
Guidance
Guidance on this call
| What | For | What management said |
|---|---|---|
| Standard ~30% growth guidance | — | We always guide about 30%, we always beat that guidance. |
| Paisabazaar significantly positive operating EBITDA | FY27 | we actually expect quite a strong year from Paisabazaar |
| Aggressive POSP growth push this year (PB Partners) | FY27 | you will find us being very aggressive this year on POSP |
What changed since the Wed 29 Oct 2025 call
| What | On the Wed 29 Oct 2025 call | On this call |
|---|---|---|
| Renewal book ARR (raised) | Renewal book ARR ₹758 Cr in Q2 FY26, up from ₹516 Cr a year earlier; described as key driver of long-term profit. | Q4 FY26 ARR ₹1,126 Cr (+63% YoY); LTM renewal revenue ₹935 Cr, up ₹267 Cr. |
| Health insurance growth (raised) | Health +60% YoY in Q2 FY26. | Health +68% YoY for full year FY26; health continues to lead the protection mix. |
| Paisabazaar profitability (raised) | Stable fixed cost base of ~₹200 Cr; profitability not firmly committed. | Operating-positive EBITDA in Q4 FY26; management expects significantly positive FY27 on operating leverage. |
| PB Connect wholesale home loans (not repeated) | PB Connect physical leg of lending business operating with retail and wholesale agents. | Wholesale POSP home-loan distribution stopped in January 2026 as not making strategic value; no profit impact. |
| PB Health strategy (new) | Investing in PB Health narrow-network and care-pathway strategy; build-out stage. | First operating hospital acquired (₹150 Cr revenue, ₹20-30 Cr profit); second hospital operationalising this month; O&M and full hospital development to converge; external fundraise in late-stage conversations. |
| Savings business trajectory (raised) | Savings business under stress for last 3-4 quarters. | Returned to growth in Q4 FY26; capital-guarantee and waiver-of-premium proposition being promoted; bond and daily-SIP mutual fund products in pipeline. |
| New initiatives growth rate (held) | New initiatives revenue +61% YoY in Q2 FY26; contribution margin 5%. | New initiatives revenue +43% YoY in Q4 FY26; EBITDA margin -4% and contribution margin 5%; now growing at similar pace as other businesses. |
The business
By business
Insurance (Policybazaar)
FY26 insurance premium ₹29,934 Cr (+42% YoY); Q4 +46% YoY; new protection premium +57% for the year, +67% in Q4 with health +68%; renewal ARR ₹1,126 Cr in Q4 (+63% YoY); PB Partners has 450,000 advisors covering 99% of PIN codes; insurance CSAT consistently above 90%.
Insurance premium ₹29,934 Cr (+42% YoY) · Q4 premium growth 46% YoY · Core online insurance premium +39% for year, +44% Q4 · New protection premium +57% YoY (year), +67% Q4 · Health insurance +68% YoY · Renewal book ARR ₹1,126 Cr Q4 (+63% YoY) · LTM renewal revenue ₹935 Cr (up ₹267 Cr) · PAT ₹670 Cr (2.2% of premium) · Operating revenue FY26 ₹6,794 Cr (+37% YoY) · Q4 operating revenue ~₹2,000 Cr
Outlook: Reiterated standard guidance of ~30% growth; aggressive POSP push planned this year with deepening into smaller cities; health expected to continue leading, term catching up.
Paisabazaar (lending)
Q4 credit revenue +7% YoY and disbursal +11% YoY; Paisabazaar CSAT now ~90% from earlier ~72%; turned operating-positive on EBITDA in Q4; fixed cost base stabilised at ~₹200 Cr; PB Connect wholesale home-loan POSP stopped (₹0.5 Cr/month loss removed).
Credit revenue +7% YoY · Disbursal +11% YoY · Operating-positive EBITDA Q4 · Paisabazaar CSAT ~90% · PB Connect wholesale business stopped January 2026
Outlook: Expect significantly positive FY27 on operating leverage; applying for stock-broking license (to enable bond distribution) and mutual fund ARN; daily-SIP mutual fund concept in development; possible listing in 4-5 years.
New initiatives (POSP/PB Partners, UAE, PB Corporate, PB Health)
Revenue grew 43% YoY with EBITDA margin at -4% and 5% contribution margin; PB Partners 450,000 advisors with 99.5% earning <₹20 lakh/year and 83% of premium from small agents (up from 50-50 a year ago); UAE +54% YoY despite March disruption; PB Corporate +140% Q4.
New initiatives revenue +43% YoY · EBITDA margin -4% · Contribution margin 5% · UAE business +54% YoY · UAE quarter +10-12% YoY · PB Corporate +140% Q4 · PB Health hospital revenue ₹150 Cr · PB Health hospital profit ₹20-30 Cr · PB Care+ network ~500 hospitals · PB Partners 450,000 advisors · 83% of POSP premium from small agents (vs 50-50 a year ago)
Outlook: Aggressive POSP growth expected this year; PB Health to raise external capital (late-stage conversations), may or may not involve PB Fintech pro-rata; PB Corporate expected to continue investing for scale; new initiatives will keep being added (PB Wheels, PB Pay, embedded insurance).
Balance sheet, capex and funding
- Capital allocation under informal management-level discussion only; buybacks and dividends mentioned but no board-level plan yet; no M&A or new growth opportunities actively pursued in last 3 months.; other
- PB Health: ~26-28% PB Fintech shareholding; PB Health has used <30% of previously raised cash; now in late-stage external fundraise conversations; second hospital goes live this month.; other
- Capex on hospital network: one operating hospital acquired in Noida (₹150 Cr revenue) and Central Gurugram hospital operationalising now; further hospitals in Delhi/Gurgaon and outside.; other
- Working capital: Paisabazaar fixed cost base stabilised at ~₹200 Cr; expected to stay similar in FY27, no incremental employee expansion planned for near-term future.; other
- PB Connect wholesale business stopped in January 2026 to remove a ~₹0.5 Cr/month loss; no balance-sheet impact material.; one_off
The industry, as management sees it
Health insurance: structural growth driven by awareness and superior customer proposition; claims costs rising industry-wide requiring participation mechanisms (co-pay, tiered networks). Life insurance savings: challenged by MF/bond alternatives but ULIP retains tax advantages and goal-protection features; industry commission structure changes (deferral, lower EOM) would benefit PB given superior persistency. Digital distribution gaining share rapidly; regulatory focus on cost sustainability of insurance pool.
Q&A
Q&A dominated by growth sustainability in health/term (60%+ for 13+ quarters), take rate and commission regulation risks (management robustly defended economics citing 20% claims ratio delta vs industry), Paisabazaar profitability timeline, PB Health capital needs, and capital allocation. Strong pushback on Paisabazaar margin trajectory and capital return timing; management deflected Paisabazaar segment margin breakdown. Most surprising signal: PB Health going beyond 2 hospitals to full O&M network operations; Paisabazaar listing aspiration mentioned informally. UAE resilience under adversity was highlighted as proof of execution culture.
Not answered directly
- Paisabazaar segment margin breakdown (insurance vs Paisabazaar split)
- Exact health vs term growth split
- Concrete capital allocation plan
Asked for a number, answered without one
- AI-driven margin benefits: Said focus is on productivity, sales conversion and customer experience, not on cost/margin optimisation; AI contribution to conversions not broken down; expected to come through 3-5 years from now.
- Health vs term split of 67% Q4 protection growth: Said only that health is ahead of term; declined to give the exact health growth number.
- Capital allocation specifics: Said no board-level discussion; only an informal management-level conversation around buybacks and dividends; no plan on what to do with capital at this point.
- PB Fintech participation in PB Health round: Said PB Fintech has a pro-rata right up to its 26-28% stake; will consider if/when it comes to the board, but PB Health has not come to PB Fintech yet.
- Long-term deferral impact on P&L vs cash flow: Said no major P&L impact under Ind AS; cash-flow impact could be strong but rules not yet out; declined to engage further on scenario speculation.
Every question, with its answer
1. New Insurance Premium Growth
Sachin Salgaonkar, Unknown
Question. What is driving the 59% YoY new insurance premium growth in Q4? Any colour on product mix, volume growth, and medium-term steady-state growth outlook?
Answer, Sarbvir Singh, Joint Group CEO. Drivers remain the same: health grew strongly post-GST, driven by superior modular product proposition and superior claims experience. Term had a great Q4 as team came together (partly favorable comp as prior year Q4 was weak). Savings returned to growth after 3-4 tough quarters (March Gulf situation hurt NRIs). We always guide 30% and always beat that guidance. Health ahead of term; all businesses contributed in Q4.
Follow-up. On steady-state growth, what could one think about?
Answer. We always guide about 30%, we always beat that guidance.
2. AI / PB AI Operating System
Sachin Salgaonkar, Unknown
Question. Can you quantify AI margin benefits from PB AI operating system in medium term?
Answer, Yashish Dahiya / Sarbvir Singh, Chairman & Group CEO / Joint Group CEO. We are not optimizing for cost/margin right now. Focus is on increasing sales team productivity, customer service quality, and customer experience. Conversions going up QoQ and YoY. Best use case in insurance is risk (identifying non-claimers before they claim; claims verification), not efficiency. Priorities for next 5 years are growth and customer excellence — not margin expansion. AI is company-wide now, not siloed.
Partly answered.
3. M&A / Capital Deployment
Sachin Salgaonkar, Unknown
Question. With huge cash flows expected, what are growth investments and adjacencies being considered? Is PB Fintech looking to invest in PB Health's next funding round?
Answer, Yashish Dahiya, Chairman & Group CEO. No other growth opportunity being explored at board or management level for last 3 months; not actively looking. PB Health is raising capital and in late-stage conversations but has not approached PB Fintech yet. PB Fintech holds 26-28% and has pro-rata rights to maintain stake; any investment would need board approval.
Follow-up. Does a possibility remain that PB Fintech might invest in PB Health at some point?
Answer. That has to come to the board; PB Fintech might consider it. It has right to maintain pro-rata stake.
4. Regulatory / Commission Caps
Sachin Salgaonkar, Unknown
Question. Any update on commission cap or tighter commission regulation discussions with the regulator?
Answer, Yashish Dahiya / Sarbvir Singh. Media is more active than regulator. No consultation paper from IRDAI seen. Two actual regulatory conversations: (1) deferred revenue in life insurance — PB welcomes this as they have industry-leading persistency; (2) lower EOM structure in health — also welcomed. These would benefit PB. Other conversations only heard from media.
5. Paisabazaar Margins
Jayant Kharote, Axis Securities
Question. Can you break down core business margins — Paisabazaar vs insurance? Has Paisabazaar turned EBITDA positive?
Answer, Alok Bansal / Santosh Agarwal, Executive Vice Chairman / CEO, Paisabazaar. We don't give that level of detail. At contribution level, both are doing well and quite similar; insurance maybe a little better. Paisabazaar is operating EBITDA positive this quarter; expect significantly positive next year. Fixed costs stabilized; operating leverage expected as revenue scales. New initiatives will not add incremental costs.
Follow-up. Where does the margin delta come from given take rate compression?
Answer. Fixed cost stabilized; operating leverage as revenue scales. New businesses won't add to incremental costs. Moving away from renewal revenue to upfront origination revenue. Paisabazaar is mostly origination revenue; renewal not significant.
6. Take Rate Sustainability
Jayant Kharote, Axis Securities
Question. If take rates are cut by 50-100 bps, how much can be passed on to the agent network or offset through AI/IVR?
Answer, Yashish Dahiya / Alok Bansal, Chairman & Group CEO / Executive Vice Chairman. On health, PB's total fully loaded costs and claims paid are under 80% vs no insurance company below ~100% — 20% profit delta vs industry. That 20% will go somewhere, whether to PB or insurer; fair outcome. They know the 95% of customers not claiming. 'I take 16% because I want to, not because I can only get 16%.' On agent pass-through: teams are already optimizing productivity regardless of commission direction. High probability of managing economics whatever happens.
7. Competitive Differentiation / New Products
Dipanjan Ghosh, Citigroup
Question. Policybazaar getting into pensions, PB Marketing, stock broking, MF ARN — how do you differentiate from peers 5 years out? How do you leverage existing customer base with data sharing?
Answer, Yashish Dahiya / Sarbvir Singh / Santosh Agarwal, Chairman & Group CEO / Joint Group CEO / CEO, Paisabazaar. Policybazaar stays focused on one problem: social security for middle class (health, term, pensions, waiver of premium). Paisabazaar has 5.8 Cr consumers (~50% of active credit Indians). Transitioning to engagement platform: bonds (stock broking license for bond distribution), daily SIP MF, credit. 'We were never market leader when we started anything; we'll find our own space.' Yashish noted Paisabazaar goal to list in 4-5 years (not board-approved).
Follow-up. On PB Connect physical lending leg — volumes low vs last quarter, any strategy change? And phygital insurance margin profile vs online?
Answer. PB Connect wholesale POSP stopped (₹0.5 Cr monthly loss). Phygital is 25% of savings/term/health; growing but share rises slowly. Economics good — same lead cost, extra conversion at high contribution margin. Quality management (claim settlement rates, loss ratios, persistency, renewal) at all-time highs. Building physical workforce management and sale quality skills.
8. Product Mix / POSP Strategy
Supratim Datta, Unknown
Question. How are post-September customers different from pre-September? Ticket size, product mix, conversion? Also on Paisabazaar MF — direct or regular funds? Is Paisabazaar aspiring to be a wealth management platform? And POSP granularity — what proportion of small agents now vs 1-2 years ago?
Answer, Sarbvir Singh / Santosh Agarwal, Joint Group CEO / CEO, Paisabazaar. Post-GST: health customers buying higher sum insured (majority now >₹10 L); unlimited sum insured products helping. Term: prices down 18%, rider attachment up (critical illness, accidental). But conversion rate improvement dwarfs product changes — more visitors buying. POSP: 99.5% of agents make <₹20 L revenue/year; 83% of premium from small agents (vs ~50-50 a year ago). Paisabazaar: MF ARN applied; plan daily SIP for affordability. Lending-centric to engagement platform; bonds and MF for savings trail revenue. 'We'll find our own space like we always do.'
9. Commission Deferral Impact
Neeraj Toshniwal, UBS Securities
Question. In a life insurance commission deferral scenario, what is the impact on revenue recognition and costs?
Answer, Yashish Dahiya / Sarbvir Singh / Alok Bansal, Chairman & Group CEO / Joint Group CEO / Executive Vice Chairman. PB has been asking for deferred payment for 10 years. On persistency-adjusted basis, impact minimal. Term insurance commission <5% on NPV basis over 30-40 year life. P&L should not see impact under Ind AS; cash flow may be impacted. PB okay both ways. Not participating in regulatory debate.
Follow-up. Will Paisabazaar deploy more resources, leading to higher expenses? Or is cost base intact with operating leverage only?
Answer. Expect significant operating leverage this year. Cost stabilized. Quality and productivity at 'Policybazaar levels' now — employee incentives as % of compensation dramatically higher. Not expanding employees; 30% leverage possible with current base.
10. Paisabazaar Disbursement Mix
Neeraj Toshniwal, UBS Securities
Question. Secured disbursements meaningfully dropped — change of strategy or unfavorable take rates?
Answer, Yashish Dahiya, Chairman & Group CEO. Only dropped in wholesale POSP distribution for one supplier. No strategic fit; stopped in January. Meaningful portion of home loans revenue gone but no profit impact (₹0.5 Cr monthly loss removed). Everything else up.
11. Capital Allocation / PB Health
Manas Agrawal, Bernstein
Question. Can you comment on capital allocation — use of balance sheet cash and accruals? Also PB Health operational update and follow-on fundraise plans?
Answer, Yashish Dahiya, Chairman & Group CEO. Capital allocation: buybacks and dividends discussed informally but not at board level; no concrete plan. PB Health: Noida hospital operational (₹150 Cr revenue, ₹20-30 Cr profit). Second hospital going live Central Gurugram this month. PB Care+ preferred network at 500+ hospitals. Future: O&M operations on selected network hospitals. PB Health has not used 30% of cash; late-stage capital raise in progress. PB Fintech may consider pro-rata participation but has no right to invest above pro-rata.
12. UAE Performance / Savings Growth
Nischint Chawathe, Kotak Securities
Question. How did UAE business fare this quarter? And when will savings business see a J-curve similar to health/term post-GST?
Answer, Yashish Dahiya / Sarbvir Singh, Chairman & Group CEO / Joint Group CEO. UAE: Despite Feb 28 bombings and AWS outage (10 days no bookings), March grew 3% YoY. Quarter grew 10-12%. Deep ownership of processes. Savings: total savings not the problem; getting it into insurance is the challenge. ULIP proposition: capital guarantee + goal-linking + waiver of premium + ₹2.5 L tax advantage = best investment. 70-75% ULIP persistency vs 3-11% active SIPs in MF. If entire industry took PB's commission levels on savings products, industry would shrink to 2% of current size.
13. Health Insurance Growth
Prayesh Jain, Motilal Oswal
Question. Has long-term policy mix picked up post-GST? And is 30% growth on this high base still achievable given 60%+ for 13 quarters?
Answer, Sarbvir Singh / Yashish Dahiya, Joint Group CEO / Chairman & Group CEO. Long-term policy proportion stable YoY; 4-5 year terms increased but overall multi-year premium share unchanged. No tricks in growth — fundamentals drive it: customer segmentation, appropriate products, well-trained sales team with GenAI tools, superior claims experience. Growth drivers are durable. Health 60%+ for 13 quarters on structural basis.
Follow-up. Claims support penetration — 250+ cities now; PB Care+ preferred network plan?
Answer. 250+ cities today; story shifting from city presence to hospital presence (PB Care+). Cataract example: planned procedure, straight to room, no billing desk. 24/7 doctor consultation on Policybazaar app. Future: wellness benefits, OPD, gym access for non-claimers (67% of customers getting nothing). For regular claimers: co-pay, tiered networks, limited networks for sustainability.
14. New Initiatives Revenue Contribution
Prayesh Jain, Motilal Oswal
Question. Could new initiatives be ~10% of revenues in 5 years?
Answer, Yashish Dahiya, Chairman & Group CEO. New initiatives will come — embedded insurance, savings, home loans, PB Care+, PB Wheels, PB Pay. Big revenue impact came from POSP (grows like wildfire). Team building right quality for 3 years. Single-lever growth not that easy going forward but 3-4 new things always in pipeline. Growth rates now similar to core. Labeling as 'new' is for disclosure purposes only.
15. New Initiatives Contribution Margin
Sanketh Godha, Avendus
Question. Contribution margin of new initiatives dipped from 5.7% to 4.3% this quarter — anything to read there?
Answer, Alok Bansal / Yashish Dahiya, Executive Vice Chairman / Chairman & Group CEO. Similar on 12-month rolling basis; quarterly mix changes happen. 'Do not focus on quarterly numbers.' Very opportune time to deepen POSP penetration — learning to go to smaller cities, model improving. More aggressive on POSP this year; competitive landscape favorable (some competitors merging, repositioning). Expect meaningful growth improvement next year; contribution margin secondary.
Follow-up. PB Corporate Business grew 140%+ — one-off or scalable? Profitability outlook vs POSP?
Answer. Still small; fastest growing corporate broker. Won prestigious banking/financial accounts. Top 8 broker in country; want to be much bigger. Small loss now; group can afford investment for years. Significantly more profitable than POSP long-term. Focus on growth and quality; profits will follow.
16. Revenue Receivables / Cash Flow
Sanketh Godha, Avendus
Question. Of ~₹6,800 Cr revenue reported, how much is recognized but not yet received from insurers (multi-year/pending receipts)?
Answer, Sarbvir Singh / Mohit Khobragade, Joint Group CEO / Head, Investor Relations. Cycle that started October'24 has run its course. Impact of one year but should start clearing now. Not a large portion of the story; growth from year-over-year is the point. Mohit can explain more in closed setting.
Partly answered.
What was said
Topic by topic, in the order it was spoken
Q4 Financial Performance · Yashish Dahiya (Chairman & Group CEO)
- Insurance premium ₹29,934 Cr, up 42% YoY (42% full year, 46% Q4); PAT ₹670 Cr at 2.2% of premium
- New protection premium grew 57% YoY (full year) and 67% YoY (Q4); health at 68% YoY continues to lead
- Core online insurance premium up 39% full year; savings business returned to growth after low cycle
- Renewal revenue rolling 12-month: ₹935 Cr, up ₹267 Cr YoY; Q4 renewal ARR at ₹1,126 Cr, up 63% YoY
- Operating revenue ₹6,794 Cr full year (37% growth); Q4 operating revenue ~₹2,000 Cr
- Credit revenue up 7% YoY; disbursals up 11% YoY; Paisabazaar EBITDA positive this quarter
Business Quality & Competitive Moat · Yashish Dahiya (Chairman & Group CEO)
- Only 5% of customers who bought insurance 10 years ago made more than one claim; 67% never claimed at all
- PB's claims ratio fully loaded at under 80% vs industry ~100% — 20% delta in profitability
- Claims experience is the 'keys to the kingdom'; CSAT consistently above 90% for insurance
- PB's book has highest persistency in industry; 70-75% persistency on ULIP vs 3-11% active SIPs in MF
- 'We want to take 16% because we want to, not because we can only get 16%' — on take rate sustainability
New Initiatives & POSP Scale · Yashish Dahiya / Sarbvir Singh
- POSP growing faster than core business; 450,000 advisors; 99% PIN code coverage
- 99.5% of agents make under ₹20 L revenue per year; 83% of premium now from small agents (vs ~50% a year ago)
- UAE grew 54% YoY; built on cross-border health, life and claims assurance program
- New initiatives now 3-4 years old; growth rate similar to core businesses; contribution margin ~5%
- Wholesale POSP home loans discontinued (₹0.5 Cr monthly loss removed); focus on retail micro-agents
Paisabazaar Turnaround · Santosh Agarwal (CEO, Paisabazaar)
- Paisabazaar EBITDA positive in Q4 (small but positive); expects significantly positive FY27
- Fixed cost base stabilized at ~₹200 Cr; operating leverage expected this year
- Transitioning from one-time origination platform to engagement platform
- Focus on quality of lending partners (larger banks/institutions); end-to-end journeys increased
- No incremental costs from new initiatives; revenue scaling drives margin improvement
PB Health Ecosystem · Yashish Dahiya / Sarbvir Singh
- One hospital operational in Noida (₹150 Cr revenue, ₹20-30 Cr profit); second hospital going live in Central Gurugram this month
- PB Care+ preferred network: 500+ hospitals; cataract example — red-carpet experience with no billing desk
- Future: O&M operations on network hospitals under PB Health brand; integration of physical and digital healthcare
- PB Health has not used 30% of cash raised; late-stage capital raise in progress
- PB Fintech holds 26-28% in PB Health with pro-rata rights; PB Health may approach PB Fintech for follow-on
Paisabazaar Future Strategy · Santosh Agarwal / Yashish Dahiya
- 5.8 Cr Paisabazaar consumers = ~50% of active credit Indians; cross-selling opportunity
- Stock broking license applied to acquire bond distribution capability; bonds = efficient consumer product
- Daily SIP format to improve affordability vs monthly SIP; mutual fund ARN license applied for
- Aspiration: engagement platform covering lending, savings (bonds, MF), wealth management
- Yashish: 'Paisabazaar goal is to list itself in 4-5 years' — not board-approved but team direction
Product & Market Dynamics · Sarbvir Singh / Yashish Dahiya
- Post-GST: customers buying higher sum insured (majority now >₹10 L in health); unlimited sum insured products gaining traction
- Term insurance: 18% price reduction drove rider attachment (critical illness, accidental protection)
- Conversion rate improvement dwarfing product/ticket changes — more visitors buying
- Health insurance: 60%+ growth for 13 consecutive quarters; 4-5 year policy terms now common
- Savings (ULIP): capital guarantee, goal-linking, waiver of premium, ₹2.5 L tax advantage = competitive proposition
Capital Allocation & Future Outlook · Yashish Dahiya
- No M&A discussions at board or management level in last 3 months; not actively looking
- Buybacks and dividends discussed at leadership level but not formally initiated
- Capital allocation: 'We don't have a plan on what to do with capital right now'
- Revenue CAGR 48% over Nov'21–FY26; PAT margin improvement from -58% to +10%
- Priority levers: growth, quality, profits (in that order); profits will follow naturally
In their words
Only 5% of customers who bought insurance 10 years ago made more than one claim. 67% never claimed at all. And this is the job that is entrusted to the insurance industry — bringing these 67% who pay premiums year on year without claiming.
Our total costs and claims paid on our book, fully loaded and delayed, are less than 80%. There is no insurance company in the country who can compete with that. That 20% profit will go somewhere, whether to us or to the insurance company. And it will be fair.
Please don't worry about my 16%. I take the 16% because I only want to take 16%. It's not because I can only get 16%.
To check next time
What management committed to on this call, or the dates they gave.
- Renewal book ARR progression toward and beyond ₹1,200 Cr trajectory given the Q4 FY26 ₹1,126 Cr print and ₹668 Cr to ₹935 Cr LTM uplift.
- Paisabazaar FY27 EBITDA trajectory; whether the 'significantly positive' commentary materialises on operating leverage from stabilised fixed costs.
- Closure of PB Health external capital raise and whether PB Fintech exercises its pro-rata right at the 26-28% level.
- POSP penetration push: small-agent premium share already at 83% (from 50-50); watch contribution margin and whether aggressive expansion hits quality.
- PB Health second hospital operationalisation in Central Gurugram this month and progress on PB Care+ 500-hospital preferred network.
- UAE business recovery post-March disruption; full Q1 FY27 print to confirm normalisation after the AWS outage and Gulf situation.
Transcript
We have not transcribed this call's recording. Read the company's transcript (PDF).
The stock after the call
| After the call | Close | Stock | Nifty 50 |
|---|---|---|---|
| Next session Wed 6 May 2026 | ₹1,701.80 | +1.27% | +1.24% |
| 5 sessions Tue 12 May 2026 | ₹1,603.30 | −4.59% | −2.72% |
| 20 sessions Wed 3 Jun 2026 | ₹1,578.50 | −6.07% | −2.61% |
From the close of Tue 5 May 2026, ₹1,680.50: the close before the call day (the call's time is not on file). Adjusted daily closes; the move includes everything else that happened in those sessions.